BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

274 related articles for article (PubMed ID: 17532207)

  • 21. High risk of contralateral breast carcinoma in women with hereditary/familial non-BRCA1/BRCA2 breast carcinoma.
    Shahedi K; Emanuelsson M; Wiklund F; Gronberg H
    Cancer; 2006 Mar; 106(6):1237-42. PubMed ID: 16475207
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Ipsilateral breast tumour recurrence in hereditary breast cancer following breast-conserving therapy.
    Seynaeve C; Verhoog LC; van de Bosch LM; van Geel AN; Menke-Pluymers M; Meijers-Heijboer EJ; van den Ouweland AM; Wagner A; Creutzberg CL; Niermeijer MF; Klijn JG; Brekelmans CT
    Eur J Cancer; 2004 May; 40(8):1150-8. PubMed ID: 15110878
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Infertility, treatment of infertility, and the risk of breast cancer among women with BRCA1 and BRCA2 mutations: a case-control study.
    Kotsopoulos J; Librach CL; Lubinski J; Gronwald J; Kim-Sing C; Ghadirian P; Lynch HT; Moller P; Foulkes WD; Randall S; Manoukian S; Pasini B; Tung N; Ainsworth PJ; Cummings S; Sun P; Narod SA;
    Cancer Causes Control; 2008 Dec; 19(10):1111-9. PubMed ID: 18509731
    [TBL] [Abstract][Full Text] [Related]  

  • 24. BRCA1 and BRCA2 mutation prevalence and clinical characteristics of a population-based series of ovarian cancer cases from Denmark.
    Soegaard M; Kjaer SK; Cox M; Wozniak E; Høgdall E; Høgdall C; Blaakaer J; Jacobs IJ; Gayther SA; Ramus SJ
    Clin Cancer Res; 2008 Jun; 14(12):3761-7. PubMed ID: 18559594
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Influence of selected lifestyle factors on breast and ovarian cancer risk in BRCA1 mutation carriers from Poland.
    Gronwald J; Byrski T; Huzarski T; Cybulski C; Sun P; Tulman A; Narod SA; Lubinski J
    Breast Cancer Res Treat; 2006 Jan; 95(2):105-9. PubMed ID: 16261399
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Development and testing of a decision aid for breast cancer prevention for women with a BRCA1 or BRCA2 mutation.
    Metcalfe KA; Poll A; O'Connor A; Gershman S; Armel S; Finch A; Demsky R; Rosen B; Narod SA
    Clin Genet; 2007 Sep; 72(3):208-17. PubMed ID: 17718858
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Ovarian pathology in risk-reducing salpingo-oophorectomies from women with BRCA mutations, emphasizing the differential diagnosis of occult primary and metastatic carcinoma.
    Rabban JT; Barnes M; Chen LM; Powell CB; Crawford B; Zaloudek CJ
    Am J Surg Pathol; 2009 Aug; 33(8):1125-36. PubMed ID: 19440148
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Tumour characteristics, survival and prognostic factors of hereditary breast cancer from BRCA2-, BRCA1- and non-BRCA1/2 families as compared to sporadic breast cancer cases.
    Brekelmans CT; Tilanus-Linthorst MM; Seynaeve C; vd Ouweland A; Menke-Pluymers MB; Bartels CC; Kriege M; van Geel AN; Burger CW; Eggermont AM; Meijers-Heijboer H; Klijn JG
    Eur J Cancer; 2007 Mar; 43(5):867-76. PubMed ID: 17307353
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The RAD51 135 G>C polymorphism modifies breast cancer and ovarian cancer risk in Polish BRCA1 mutation carriers.
    Jakubowska A; Gronwald J; Menkiszak J; Górski B; Huzarski T; Byrski T; Edler L; Lubiñski J; Scott RJ; Hamann U
    Cancer Epidemiol Biomarkers Prev; 2007 Feb; 16(2):270-5. PubMed ID: 17301259
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Tissue and serum MUC1 mucin detection in breast cancer patients.
    Croce MV; Isla-Larrain MT; Demichelis SO; Gori JR; Price MR; Segal-Eiras A
    Breast Cancer Res Treat; 2003 Oct; 81(3):195-207. PubMed ID: 14620915
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Increased chromosomal radiosensitivity in women carrying BRCA1/BRCA2 mutations assessed with the G2 assay.
    Ernestos B; Nikolaos P; Koulis G; Eleni R; Konstantinos B; Alexandra G; Michael K
    Int J Radiat Oncol Biol Phys; 2010 Mar; 76(4):1199-205. PubMed ID: 20206018
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effect of reproductive factors and oral contraceptives on breast cancer risk in BRCA1/2 mutation carriers and noncarriers: results from a population-based study.
    Lee E; Ma H; McKean-Cowdin R; Van Den Berg D; Bernstein L; Henderson BE; Ursin G
    Cancer Epidemiol Biomarkers Prev; 2008 Nov; 17(11):3170-8. PubMed ID: 18990759
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Impact of Helicobacter pylori infection on the humoral immune response to MUC1 peptide in patients with chronic gastric diseases and gastric cancer.
    Klaamas K; Kurtenkov O; von Mensdorff-Pouilly S; Shljapnikova L; Miljukhina L; Brjalin V; Lipping A
    Immunol Invest; 2007; 36(4):371-86. PubMed ID: 17691020
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Predictors of occult neoplasia in women undergoing risk-reducing salpingo-oophorectomy.
    Lamb JD; Garcia RL; Goff BA; Paley PJ; Swisher EM
    Am J Obstet Gynecol; 2006 Jun; 194(6):1702-9. PubMed ID: 16731090
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Use of expression data and the CGEMS genome-wide breast cancer association study to identify genes that may modify risk in BRCA1/2 mutation carriers.
    Walker LC; Waddell N; Ten Haaf A; ; Grimmond S; Spurdle AB
    Breast Cancer Res Treat; 2008 Nov; 112(2):229-36. PubMed ID: 18095154
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The predominant role of surgery in the prevention and new trends in the surgical treatment of women with BRCA1/2 mutations.
    Fatouros M; Baltoyiannis G; Roukos DH
    Ann Surg Oncol; 2008 Jan; 15(1):21-33. PubMed ID: 17940826
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A functional polymorphism in the miR-146a gene and age of familial breast/ovarian cancer diagnosis.
    Shen J; Ambrosone CB; DiCioccio RA; Odunsi K; Lele SB; Zhao H
    Carcinogenesis; 2008 Oct; 29(10):1963-6. PubMed ID: 18660546
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Hormone replacement therapy is more prevalent among Jewish BRCA1/2 mutation carriers.
    Sade RB; Chetrit A; Figer A; Papa MZ; Flex D; Rizel S; Friedman E
    Eur J Cancer; 2006 Mar; 42(5):650-5. PubMed ID: 16464572
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Histopathological findings and follow-up after prophylactic mastectomy and immediate breast reconstruction in 100 women from families with hereditary breast cancer.
    Isern AE; Loman N; Malina J; Olsson H; Ringberg A
    Eur J Surg Oncol; 2008 Oct; 34(10):1148-54. PubMed ID: 18434071
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Prognosis of early-onset breast cancer based on BRCA1/2 mutation status in a French population-based cohort and review.
    Bonadona V; Dussart-Moser S; Voirin N; Sinilnikova OM; Mignotte H; Mathevet P; Brémond A; Treilleux I; Martin A; Romestaing P; Raudrant D; Rudigoz RC; Lenoir GM; Lasset C
    Breast Cancer Res Treat; 2007 Jan; 101(2):233-45. PubMed ID: 17061047
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.